Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Recruiting
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
Recruiting
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
11/01/2024
Locations: University of Rochester, Rochester, New York
Conditions: DLBCL, Lymphoma, B-Cell
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
Completed
RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/31/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer, Nausea and Vomiting
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Terminated
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: The Oncology Institute of Hope and Innovation, Tucson, Arizona +140 locations
Conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Rapid Administration Pilot for Infusing Dinutuximab
Suspended
Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
10/30/2024
Locations: Childrens Hospital Los Angeles, Los Angeles, California
Conditions: Neuroblastoma
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Completed
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UC San Diego-Moores Cancer Center, La Jolla, California +32 locations
Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +431 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Recruiting
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Mount Sinai- Icahn School of Medicine, New York, New York +3 locations
Conditions: Richter Syndrome, Chronic Lymphocytic Leukemia
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Completed
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/28/2024
Locations: City of Hope Cancer Center, Duarte, California +2 locations
Conditions: Peripheral T Cell Lymphoma
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Completed
This study proposes the use of a reduced intensity chemotherapy/radiation therapy regimen followed by stem cell transplantation, as compared to standard ablative chemotherapy regimens associated with stem cell transplantation, in a population of patients with non-malignant diseases (non-cancer). Eligible patients will have a non-malignant disease in one of the following four strata: bone marrow failure syndromes, immunodeficiencies, inborn errors of metabolism, or histiocytoses. Patients will be... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
10/28/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Recruiting
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are att... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina +1 locations
Conditions: Peripheral T Cell Lymphoma